Diagnostic Utility of Cytomegalovirus Nucleic Acid Testing during Antigenemia-Guided Cytomegalovirus Monitoring after Hematopoietic Stem Cell Transplantation or Liver Transplantation
| Autor: | Katsunori Yanagihara, Sayaka Mori, Yoshitomo Morinaga, Yasushi Miyazaki, Masaaki Hidaka, Susumu Eguchi, Mitsuhisa Takatsuki, Jun Taguchi, Yasushi Sawayama |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty endocrine system Time Factors Adolescent medicine.medical_treatment Congenital cytomegalovirus infection Cytomegalovirus Hematopoietic stem cell transplantation Liver transplantation Nucleic Acid Testing Gastroenterology General Biochemistry Genetics and Molecular Biology 03 medical and health sciences Young Adult 0302 clinical medicine Internal medicine medicine Humans 030212 general & internal medicine pre-engraftment phase Antigens Viral Aged automation medicine.diagnostic_test business.industry nucleic acid test fungi Hematopoietic Stem Cell Transplantation Nucleic acid test virus diseases General Medicine Middle Aged medicine.disease Liver Transplantation Transplantation Liver transplant recipient immunocompromised monitoring surgical procedures operative Nat 030220 oncology & carcinogenesis Cytomegalovirus Infections Female business Nucleic Acid Amplification Techniques |
| Zdroj: | The Tohoku Journal of Experimental Medicine. 247(3):179-187 |
| ISSN: | 0040-8727 |
| Popis: | Cytomegalovirus (CMV) is an opportunistic pathogen, and careful monitoring of CMV is important for immunocompromised patients. Antigenemia-based CMV monitoring is a standard test used for managing CMV infection in transplant recipients;however, in Japan, there are no reports of CMV monitoring using the standardized test. The utility of a standardized CMV nucleic acid test (NAT) was evaluated during antigenemia-based CMV monitoring after hematopoietic stem cell transplantation (HSCT) or liver transplantation. Blood collection for CMV monitoring was performed under the physician's instructions depending on the condition of the patient, and CMV NAT and antigenemia was evaluated. For HSCT recipients, blood collection only for NAT was additionally performed during the pre-engraftment phase. The results of the NAT were blinded to those evaluating the results. A total of 34 patients were enrolled (11 HSCT recipients and 23 liver transplant recipients). NAT detected the first CMV episode no later than antigenemia in 2 (18.2%) HSCT recipients and 3 (13.0%) liver transplant recipients, earlier than antigenemia in 3 (27.3%) HSCT recipients and 7 (30.4%) liver transplant recipients, and later than antigenemia in 1 (9.1%) HSCT recipient and 1 (4.3%) liver transplant recipient. In 5 HSCT recipients, NAT was positive during the pre-engraftment phase. Among the 468 blood samples which were evaluated by both NAT and antigenemia, 124 (26.7%) were positive in NAT and 51 (10.9%) were positive in antigenemia. The standardized CMV NAT is useful for accurately diagnosing CMV infection and determining appropriate therapeutic interventions for HSCT recipients and liver transplant recipients. The Tohoku journal of experimental medicine, 247(3), pp.179-187; 2019 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|